Clinical Research Directory

Inclusion Criteria: * Has histologically or cytologically confirmed advanced or metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC); advanced or metastatic NSCLC; or advanced, unresectable, or metastatic pancreatic ductal adenocarcinoma (PDAC) * Has histologically confirmed unresectable locally advanced or metastatic colorectal adenocarcinoma or squamous cell carcinoma of the esophagus; advanced or metastatic adenocarcinoma of the esophagus, gastroesophageal junction (GEJ), or gastric/stomach that is considered incurable by local therapies; or recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) of the oral cavity, oropharynx, hypopharynx, and/or larynx that is considered incurable by local therapies * Has provided archival tumor tissue sample or newly obtained biopsy of a tumor lesion not previously irradiated * If human immunodeficiency virus (HIV)-infected, has well-controlled HIV on antiretroviral therapy (ART) * If hepatitis B surface antigen (HBsAg)-positive, has received HBV antiviral therapy for at least 4 weeks and has undetectable hepatitis B virus (HBV) viral load * If history of hepatitis C virus (HCV) infection, has undetectable HCV viral load * Has adequate organ function Exclusion Criteria: * Is HIV-infected with history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has received prior systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to allocation/randomization * Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids * Has known additional malignancy that is progressing or has required active treatment within the past 2 years * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Has a history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, except for a history of radiation pneumonitis that did not require steroids; current diagnosis of ILD; or clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out * Has active infection requiring systemic therapy other than those permitted in the protocol * Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Has uncontrolled significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, uncontrolled symptomatic arrhythmia, prolongation of corrected QT interval by Fridericia (QTcF) to \>470 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention * Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention * Has not adequately recovered from major surgery or has ongoing surgical complications